Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Age Related Macular Degeneration Companies

Age-related macular degeneration (AMD) is a progressive eye disease that affects the macula, leading to central vision loss. Several companies are involved in the development of diagnostic tools, therapies, and research related to AMD.

Age-Related Macular Degeneration Key Companies Disclaimer: List of key companies in no particular order

Latest Age-related macular degeneration Companies Update

October 2023: The Food and Drug Administration approved Endogena's medication for age-related macular degeneration. EA-2351 will be the subject of a clinical study for geographic atrophy by the business. Geographic atrophy (GA) is a severe type of age-related macular degeneration (AMD), and the FDA has approved an experimental new medication application from Endogena Therapeutics to treat it. Endogena will be allowed to move on with clinical testing of EA-2350 now that it has received FDA approval to do so. Among those aged 45 and up, AMD is the major cause of permanent visual loss and is estimated to afflict 9 percent of the population. GA is a persistent, progressive degeneration of the macula that occurs as a result of advanced AMD and can eventually cause permanent vision loss.

October 2023: Vabysmo (faricimab) was authorized by the U.S. Food and Drug Administration (FDA) in October 2023 for the treatment of macular edema caused by retinal vein occlusion (RVO), as stated by Roche. RVO joins neovascular or 'wet' age-related macular degeneration (nAMD) and diabetic macular edema (DME) as Vabysmo's indications. About 70 million individuals worldwide suffer from one of these three retinal diseases, making them major contributors to blindness. Vabysmo is a novel therapy for RVO that has the extra benefit of drying the retina, allowing patients to maintain or even enhance their eyesight. Hundreds of thousands of patients have been successfully treated, attesting to the safety and effectiveness of Vabysmo in both clinical studies and the real world.

List of Age-related macular degeneration Key companies in the market

Hoffmann-La Roche AG

Bausch & Lomb Incorporate

Novartis AG

Pfizer Inc

ALLERGAN

Acucela Inc.

Santen Pharmaceuticals Co.

Ophthotech Corporation

Alimera Sciences Inc.

GlaxoSmithKline PLC

Regeneron Pharmaceutical Inc.

Bayer AG

Rxi Pharmaceuticals Inc.

Age Related Macular Degeneration Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.